TickerSpark Feed

nasdaq

Everything tagged "nasdaq" across the TickerSpark archives.

Deep Sea Minerals Corp. Goes Public: The Deep-Sea Rights Play
IPOSEAM

Deep Sea Minerals Corp. Goes Public: The Deep-Sea Rights Play

Deep Sea Minerals Corp. American Depositary Shares (NASDAQ: SEAM) is expected to list on 2026-10-30, but the price range has not been disclosed yet. The company is pitching a licensing-first way to access deep-sea mineral assets in the Cook Islands EEZ, the U.S. EEZ, and the Clarion-Clipperton Zone. Bull case: a large addressable resource story tied to critical minerals. Bear case: no revenue, widening losses, and a long, uncertain path to commercial production.

Oct 29, 20265 MIN
What to Watch as Bambusa Therapeutics Prices Its Nasdaq IPO
IPOBBTX

What to Watch as Bambusa Therapeutics Prices Its Nasdaq IPO

Bambusa Therapeutics Inc. (Nasdaq: BBTX) is expected to list on 2026-10-30, with pricing already set for the NASDAQ. The company has not disclosed a price range, but it sold 10,555,555 shares at $16.00 each for $168.9 million in gross proceeds. Bulls will focus on its long-acting bispecific pipeline in immunology and inflammation; bears will focus on clinical risk and a cash runway that the company says is not enough to fund 12 months of operations.

Oct 27, 20265 MIN
The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

Daily market recap + weekly preview. One-click unsubscribe in every email.

Inside the Apex Critical Metals Corp. IPO: Setup, Risks, and Verdict
IPOAPXC

Inside the Apex Critical Metals Corp. IPO: Setup, Risks, and Verdict

Apex Critical Metals Corp. American Depositary Shares (NASDAQ: APXC) is expected to list on 2026-10-23, but the price range has not been disclosed. The company is a pre-revenue rare earths and niobium explorer, so the setup hinges on drill progress, funding, and how investors price critical-minerals optionality. Bull case: U.S.-linked critical minerals exposure; bear case: no revenue, no disclosed pricing, and heavy exploration risk.

Oct 23, 20265 MIN
Davion Healthcare Prices Nasdaq Direct Listing on Home Testing Push
IPODAVI

Davion Healthcare Prices Nasdaq Direct Listing on Home Testing Push

Davion Healthcare Plc is set to list on Nasdaq on 2026-10-22, with a price range not disclosed and a market cap of $252,750,000. The company is coming public as a direct listing, so there is no traditional underwritten IPO bookbuild or IPO proceeds. The bull case is a pre-revenue medtech story with multiple registered products and a consumer OTC model. The bear case is that the stock starts trading without the cushion of an IPO raise, while cash remains extremely thin and execution risk is high.

Oct 21, 20266 MIN
Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float
IPOIDXG

Interpace Biosciences Uplisting: Thyroid Testing Growth Meets a Tight Float

Interpace Biosciences, Inc. (NASDAQ: IDXG) is expected to list on 2026-10-21, with a $6.00-$7.00 price range and 3.1 million shares offered. The company is already public on OTC-style markets, so this is an uplisting and offering rather than a classic first-time IPO. Bull case: a profitable thyroid diagnostics niche with growing revenue; bear case: customer concentration and reimbursement risk still matter.

Oct 20, 20266 MIN
On-Demand Research

Need research on a stock not covered here?

Generate AI research on any ticker — grades, price targets, and full analysis in minutes.

Open the Generator